Actinium Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference Sep 8, 2022
Actinium Pharmaceuticals, Inc. Announces 82% of Control Arm Patients Did Not Receive a Bone Marrow Transplant by Conventional Means but 100% of Patients who Received Iomab-B, Including Crossover Patients, in the Phase 3 SIERRA Trial Successfully Engrafted at the Transplantation & Cellular Therapy Tandem Meetings of ASTCT and CIBMTR Apr 25, 2022
Actinium Pharmaceuticals, Inc. to Highlight Iomab-B Pivotal Phase 3 SIERRA Trial Data at the Transplantation & Cellular Therapy Tandem Meetings of ASTCT and CIBMTR Apr 19, 2022
Actinium Pharmaceuticals, Inc. and Immedica Announce Commercialization Agreement for Iomab-B (131I apamistamab) in Europe, the Middle East and North Africa Apr 12, 2022
Actinium Pharmaceuticals Presents Preclinical Data at AACR Showing HER3 Targeted Radiotherapy Combined with the CD47 Immunotherapy Magrolimab Increases the Anti-tumor Effect Apr 11, 2022
Actinium Pharmaceuticals, Inc. and EpicentRx Announce Strategic Research Collaboration to Combine Targeted Radiotherapies with Next Generation CD47/SIRPĪ± Immunotherapy Jan 5, 2022
Actinium Pharmaceuticals, Inc. Announces 72% MRD Negativity Rate in the Recently Completed Phase 1 Study of Actimab-A in Combination with CLAG-M for Patients with Relapsed or Refractory AML Dec 14, 2021
Actinium Pharmaceuticals, Inc. Reports 2 Remissions and 67% ORR in Patients with a TP53 Mutation in the Phase 1 portion of the Actimab-A Venetoclax Combination Trial in Patients with Relapsed or Refractory AML at the 63rd ASH Annual Meeting Dec 14, 2021
Actinium Pharmaceuticals, Inc. Announces Greater Difference of Approximately 5x for Iomab-B vs Control Arm in the Number of Patients Potentially Evaluable for the Primary Endpoint of the Pivotal Phase 3 SIERRA Trial at the 63rd ASH Annual Meeting Dec 13, 2021
Actinium Pharmaceuticals, Inc. Announces Participation in Two Panel Discussions at the 3rd Targeted Radiopharmaceuticals Summit Dec 8, 2021
